Clinical Trial Update: Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating donor CMV-specific cytotoxic T lymphocytes for persistent cytomegalovirus infection in patients with hematologic malignancies …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection
• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Donor CMV-specific cytotoxic T lymphocytes

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING